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Abstract
Background: The accurate diagnosis and effective prevention and control of tuberculosis (TB)
are major global public health challenges. Ecuador has among the highest documented TB
incidence (59/100,000 inhabitants) and mortality rates in the Americas region (27/100,000
inhabitants). In addition, TB multi-drug resistance is becoming increasingly common. The
culture method is the preferred method of choice for diagnosing TB in the United States and
many other high resource countries due to its high documented sensitivity. An added benefit of
the methods is that it also can be used to detect primary TB resistance. In contrast, despite its
lower diagnostic sensitivity, the sputum smear method is most often used in low resource
countries with a high disease burden, including Ecuador. The main reason for this is due to its
lower cost, quick turnaround time and reduced technology requirements. However, scarce data
have been published comparing the diagnostic properties of the two methods in a high-volume
public health care setting such as in Ecuador or other low resource neighboring countries.
Methods: The major objective of the cross-sectional study was to compare the diagnostic
properties of the sputum smear with the culture method with respect to sensitivity, specificity,
and predictive value. Another objective was to reveal the prevalence of drug-resistance. The data
were collected from a consecutive sample of 1487 suspected TB cases referred during a 12month period (1999-2000) by public health care professionals to the Instituto Nacional de
Higiene “Leopoldo Izquieta Perez” National Laboratory in Quito, Ecuador. Results: The study
displays a low sensitivity (58%) while the specificity was high (97.8%). Of 10% of the sample
size, 32% exhibited drug resistance (9% single drug, 23% multi-drug) and 4 cases of complete
resistance. Conclusion: The findings suggest there is a low sensitivity when using sputum smear
as the standard diagnostic exam. In describing the drug-resistance in the sample, it was found
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that Isoniazid was the drug that showed the most resistance (3.8%). In multi-drug resistance,
Isoniazid with Rifampicin had the most reported drug resistance (7.9%). This means that high
levels of isoniazid and rifampicin resistance show that some of these patients used these drugs to
treat a non-tuberculosis infection. Recommendations are to use culture as a standardized test in
unison with sputum smear, and to create an intensive monitoring program of treatment and
surveillance for tuberculosis and tuberculosis resistance.
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Chapter 1: Background and Significance
1.1 Epidemiology of Tuberculosis
Tuberculosis [TB] prevention and control is a major public health priority of global
importance. Estimated global TB prevalence and mortality rates have significantly dropped since
1990 but not at a rate that has halved the amount of cases (WHO Guidance, 2010). Even more
alarming is the rise of drug-resistant tuberculosis and HIV-associated TB that threaten TB
control and prevention (WHO Guidance, 2010).
In 2010, there was an estimated 8.8 million incident cases of TB in the world, which is
approximately 128 cases per 100,000 persons (WHO Global, 2012). Most global TB cases are
found in Asia (59%) and Africa (26%) (WHO Global, 2012). The five countries with the highest
TB burden are Indonesia (0.5 million-0.28 million), China (0.9 million-1.2 million), Pakistan
(0.33 million-0.48 million), South Africa (0.40 million-0.45 million), and India (2 million-2.5
million) (WHO Global, 2012). India alone accounted for one quarter (26%) of all TB cases
globally in 2011 (WHO Global, 2012). Moreover, China and Indonesia together were
accountable for 38% of cases (WHO Global, 2012). Globally, thirty-six percent of all TB cases
are estimated to be women (WHO Global, 2012). Since 1990, documented global TB cases have
significantly decreased. However, HIV and TB,	
  together accounted for 0.35 million-deaths
(WHO Global, 2012). The Millennium Developmental Goal [MDG] 6 by the World Health
Organization was organized to combat HIV/AIDS, Malaria, and other diseases (WHO Global,
2012). MDG 6c plans to have halted and reverse the incidence of malaria and tuberculosis by
2015 (WHO Global, 2012). Worldwide, the MDG 6c target is on track for reversing TB
incidence by 2015 (WHO Global, 2012). The WHO is using the Stop TB Strategy to achieve the
MDG target. The strategy involves high-quality Drug Observed Therapy [DOTS] expansion;
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addressing TB/HIV, multidrug-resistant TB; contributing to health system strengthening;
engaging all care providers; empowering people with TB, and communities through partnership;
and promoting research (WHO Global, 2012).
Latin American countries face significant problems with tuberculosis. The World Health
Organization continues to list Brazil as one of the top TB-burdened countries - ranking Brazil
15th in the world in 2003 (WHO Global, 2012). Among burden estimates of TB including HIV
cases, Brazil has a prevalence of 46 cases per 100,000 persons and an incidence of 85 cases per
100,000 persons (WHO Global, 2012). In new cases reported for 2012, 31% of reported cases
had a TB relapse (WHO Global, 2012).
Mexico exhibits a lower prevalence (28 cases per 100,000) and incidence (18 cases per
100,000); however, a relapse rate of 57% is reported (see Table 1) (WHO Global, 2012). A
central problem in Mexico and Latin American countries is the lack of an active surveillance
system for asymptomatic cases of TB. Fluidity between the US-Mexico border drives
transmission of TB infections, there has been a rising emphasis on policy-making (Fitchett et al.,
2011). Essential improvements to surveillance systems include a registry of cases, funding for
services, and system to find infected patients and their close contacts; which is reflective of the
need in Latin American countries (Fitchett et al., 2011). A controlled trial of active tuberculosis
case-finding within a Brazilian drug and violence ridden area found that a door-to-door casefinding campaign was effective in detecting prevalent cases and persuading people to initiate
participation in care (Cavalcante et al., 2010).
Drug resistance is increasing worldwide. Zignol and associates report of drug resistance
around the world finds many countries still lack reliable MDR-TB surveillance systems (Zignol
et al., 2007). The World Health Organization and International Union Against Tuberculosis
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conducted a survey in 35 geographic sites in Pakistan (Irfan et al., 2006). They found that the
prevalence of primary resistance to at least one anti-TB drug was around 10.7% (Irfan et al.,
2006). The trend in rising retreatment cases in comparison to MDR in pulmonary TB is evident
in most countries in Latin America (see Table 1).
Among the 12 million TB cases of in the world, the World Health Organization reports
650,000 of those cases were multi-drug-resistant MDR-TB (WHO Global, 2012). However; the
World Health Organization cannot provide accurate estimates by country on MDR for various
causes. Reasons for inaccurate estimates include a lack of definitive assessment, input of data,
parameters used, over-reportage due to duplication of cases, and extrapolation used to input
missing data (WHO Global, 2012).
Peru is reported to be affected less by HIV; however, it is affected by a significant relapse
rate (66%) and substantial multi-drug resistant tuberculosis (5.6%) in the population (WHO
Global, 2012). In 2011, there were 1200 new cases of MDR-TB among pulmonary TB and 860
retreatment cases (WHO Peru, 2011). Peru leads in new reported cases of MDR-TB and
retreatment cases in Latin America.
Less than half of tuberculosis patients in Latin America and the Caribbean are currently
tested for HIV, and persons living with HIV are not always screened for tuberculosis even
though they exhibit symptoms (PAHO, 2011). Consequently, most people in this region who are
infected with both TB and HIV are not aware of their medical condition (PAHO, 2011). Most
importantly, they are not receiving treatment for the reduction and/or elimination of both
diseases to prevent transmission and death in the population (PAHO, 2011). Both WHO and
PAHO public health experts agree the problem stems from a lack of coordination between
HIV/AIDS and TB programs (PAHO, 2011).
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1.2 Transmission of Tuberculosis
Transmission of TB occurs when an individual is exposed to airborne respiratory droplets
caused by an infected person with pulmonary or laryngeal TB sings, sneezes, and/or coughs into
the environment (CDC Ch2, 2012). These droplet nuclei can remain suspended in the air for
several hours (CDC Ch 2, 2012). M. tuberculosis is spread by air and not by surface contact.
Transmission of TB initially occurs when a person inhales contaminated droplet nuclei. Next, the
droplet nuclei enter the body by traversing the nasal or mouth passages to the upper respiratory
tract to reach the alveoli of the lungs where infection begins (CDC Ch2, 2012).
Transmission of TB is dependent on length, time, and frequency of exposure, airflow in
environment where exposure occurred, and the length of contact with the TB bacteria (CDC Ch2,
2012). This explains why it is easier to be infected with tuberculosis from a household contact
than a casual contact because prolonged contact in an enclosed space increases risk. High-risk
areas for tuberculosis infection are overcrowded places, such as homeless shelters, prisons,
nursing homes, and hospitals CDC Ch2, 2012).
A single person with tuberculosis can potentially infect about ten or more people in one year
(CAMFIL, 2012). The cough from an infected person can release 3000 infectious droplet nuclei
into the room (CAMFIL, 2012). These easily transmissible microscopic droplets are rod-shaped,
2-4 microns in length, and 0.2 - 0.5 microns in length (CAMFIL, 2012). The infected person may
spread TB droplets through singing, talking, sneezing, and playing wind instruments (CAMFIL,
2012). Sneezing generates the most droplet nuclei that can reach people up to ten feet away
releasing tens of thousands droplets into the environment (CAMFIL, 2012). Tubercle bacilli are
killed by direct sunlight. However, they can survive in the dark for several hours increasing the
risk for infection (CAMFIL, 2012).
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Factors that determine the probability of transmission of M. tuberculosis are susceptibility,
infectiousness, environment, and exposure (Falzon et al., 2011). The determinant of the
infectiousness of an individual is the extent to how many tubercle bacilli he or she expels into the
air (Falzon et al., 2011). The more tubercle bacilli in the air, the more infectious the person is.
Environmental factors that enhance tuberculosis infection are the concentration of infectious
droplet nuclei in the air, inadequate ventilation that results in insufficient dilution of the droplet
nuclei, recirculation of air containing infectious droplet nuclei, and positive air pressure in
infectious patient’s room that allows tubercle bacilli to flow to other areas (CDC Ch2, 2012).
1.3 Risk Factors
Major risk factors for TB include aging, immunosuppression, high alcohol intake, smoking,
malnutrition, HIV/AIDS, and diabetes mellitus. A systematic review conducted by Lönnroth and
associates reported there is a three-fold risk increase of active TB associated with consumption
of more than 40 g alcohol per day, and/or having an alcohol use disorder (Lönnroth et al., 2008).	
  
Animal studies suggest that cell mediated immunity and macrophage functions are directly
impaired by chronic and acute alcohol consumption (Lönnroth et al., 2008). Through inhibited
tumor necrosis factor (TNF) response, alcohol may also diminish the nitric oxide (NO)
microbicidal response to Mycobacterial infection (Lönnroth et al., 2008). This in turn may
prevent the elimination of Mycobacteria from infected tissue.
Smoking increases the iron in the body so that broncho-alveolar macrophages reduce in host
defense thereby increasing the risk of TB infections (CAMFIL, 2012). There are three main
ways that cigarette smoking can initiate infection with Mycobacteria and how the infection
evolves into active TB disease. For example, smoking alters the immune system making it less
viable to fight TB infection, and smoking reduces the effectiveness of TB treatment, which can
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lead to longer periods of infection and/or more severe forms of the disease (CAMFIL, 2012).
Developing latent TB infection appears to be increased three-fold in smokers compared to nonsmokers (CAMFIL, 2012). For persons with latent TB infection, cigarette smoking increases
their risk of developing active TB disease by two to three times, compared to non-smokers
(CAMFIL, 2012). Air pollution from outdoor sources, such as motor vehicles, industry, and
neighborhood-level solid waste burning, is associated with increased morbidity and mortality
from respiratory infections (Cohen et al., 2007). People in urban areas of developing countries
are exposed to the highest levels of outdoor air pollution in the world. Each year millions of
years of healthy life is lost from cardiovascular disease, selected respiratory diseases, and lung
cancer (Cohen et al., 2007). A study in Los Angeles shows a correlation between particulate
matter [PM] 2.5 in residential areas near freeways and smear-positive status (Jassal et al., 2012).	
  	
  
Tuberculosis mortality rates in different economic groups tend to vary inversely with their
economic levels (Gupta et al., 2009). The role of malnutrition is an important risk factor in
activating TB infection or disease. Malnutrition profoundly affects cell-mediated immunity
[CMI] (Gupta et al., 2009). CMI is the central factor in defending the body against TB. TB
disease can itself lead to malnourishment because of decreasing appetite and changes in
metabolic processes (Abba et al., 2008). BCG vaccine trials in the late 1960s showed an
association between malnutrition and TB estimating that malnourished children are twice as
likely to develop TB disease as to nourished groups (Comstock et al., 1966). In an Indian study,
tuberculosis patients were 11 and 7 times more likely to have a BMI < 18.5 and mid-arm
circumference < 24 cm (Shetty et al., 2006).
Aging is associated with decreases in immune function (Bruunsgaard et al., 2001). Thus,
elderly persons may be more susceptible to acquiring TB infection when exposed to individuals
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with active TB (Bruunsgaard et al., 2001). Infection primarily occurs in community dwellings
(e.g. nursing homes) in 80 -90% of TB cases among elderly persons (Bruunsgaard et al., 2001).
There is a 2-3-fold increase of active tuberculosis among nursing home residents (Bruunsgaard et
al., 2001). Findings from animal model studies suggest that there is an age-related decline of Tcell response, which increases the risk of infection by intracellular pathogens, such as M.
tuberculosis (Bruunsgaard et al., 2001). While immune deregulation is involved in the
reactivation of prior infection in the elderly, age-associated diseases play a major role in
enhancing the threat of tuberculosis among elderly populations (Bruunsgaard et al., 2001). These
include conditions such as chronic renal failure, malnutrition, diabetes mellitus, HIV/AIDS and
malignancies. This occurs not only in aging.
Chronic exposure to indoor pollution is another factor that may increase vulnerability to
acquire TB. Half of the world’s population depends on solid fuels, including biomass (wood,
dung, and agricultural residues) and, coal to meet basic needs such as cooking, boiling water, and
heating (WHO Sec1, 2012). Emerging evidence in Mexico implies a causal role in the incidence
of TB is increased among biomass fuel-exposed women (Perez-Padilla et al., 2001). Overall, the
evidence supports the notion that exposure to respirable pollutants from combustion of biomass
fuels increases the risk of TB infection and disease. Biomass fuels impair the alveolar
macrophage function (Aam et al., 2007). Alveolar macrophages are not only the target of
Mycobacterium tuberculosis infection but also contribute an important early defense mechanism
against bacteria (Fullerton et al., 2008). However, these circumstances are not relatable for
everybody in Latin America. Cooking with solid fuels is not practiced in every single home
throughout Latin America.
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HIV/AIDS, and diabetes mellitus are illnesses that cause persons to be susceptible to
tuberculosis infection and disease (see Table 2) (CDC Ch2, 2012). These illnesses are not
prevalent in every country but it is dominant in developing countries, particularly in Latin
America. Today, 350 million people in the world have diabetes (CDC Ch2, 2012). Eighty
percent of diabetes-related mortality occurs in low to middle income countries (CDC Ch2, 2012).
Diabetes can increase risk of developing TB by up to 30% throughout a lifetime (CDC Ch2,
2012). In Mexico, the investigation of a national representative sample of 2,716 smear positive
cases of TB showed that overall 22% of the total sampled cases were also persons with
diagnosed diabetes (Secretaria de Salud Mexico, 2009).	
  HIV/AIDS is the co-morbid condition
most often associated with TB. It can increase risk by 7-10% per year for developing
tuberculosis (CDC Ch2, 2012).
1.4 Drug-Resistance
Drug resistance is an increasing important challenge for TB control worldwide. Primary
resistance is when a person is first infected with resistant organisms (CDC Ch 2, 2012).
Secondary resistance occurs when an individual did not adhere to the drug regimen or correctly
or other conditions such as drug malabsorption (CDC Ch2, 2012). Multi-drug resistance is
strains resistant to isoniazid and rifampicin where second line drugs are needed (CDC Ch2,
2012). Tuberculosis drug-resistant risk factors involve the inadequate or irregular supply of
drugs, misuse of prescriptions, and poor drug quality result in discontinued treatment or lack of
treatment compliance (Aziz et al., 2005). In Armijos et al, four in ten subjects (36.7%; 18/49)
admitted that either they or their family member had stopped taking their TB medications for one
or more weeks without physician consent (Armijos et al., 2008). Reasons for non-compliance
were a lack of money to buy the TB medications (38.9%; 7/18), the patient felt cured (33.3%;
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6/18), intolerable drug side effects (22.2%; 4/18), a drug shortage at the treatment facility (5.6%;
1/18), or inability to get permission to leave work to pick up the medications (5.6%; 1/18)
(Armijos et al., 2008).	
  Prescription misuse includes behaviors such as discontinuing antibiotics
before treatment completion and shifting prescribed doses of antibiotics from requirements (Aziz
et al., 2005). This can suppress the growth of susceptible bacilli meanwhile permitting drugresistant bacilli to reproduce making the drug ineffective during treatment (Aziz et al., 2005).
Implementing the sputum smear microscopy [SSM] as a gold standard is also a risk factor to
drug-resistance, since it exhibits false-negatives and thus clears the infected person to transmit
the disease to the community.	
  
Primary resistance can develop when exposed to a person who has single drug-resistant TB
disease (CDC Ch2, 2012). It can also occur with exposure to a person who had prior treatment
for TB and suffered possible relapse or lives in an area of high prevalence of drug resistance
(CDC Ch2, 2012). The same risk of developing resistance occurs if the individual is exposed to a
person with MDR-TB strains. However, the cure rate for MDR is low, only 6 to 59% (Aziz et al.,
2005). Drug-resistance is an important public health issue since it costs the pharmaceutical sector
billions of dollars and several years to develop new drugs in order to treat drug-resistant strains
of tuberculosis. This problem is present all over Latin America.
Due to the political instability in Latin America, management factors can also contribute to
risks in tuberculosis and multi drug resistant tuberculosis (Aziz et al., 2005). Management of
tuberculosis in Latin America is difficult within its own health infrastructure: public health
facilities. There is poor program implementation, frequent shortages of drugs, few qualified
health workers and inadequate resources, and a lack of political commitment (Aziz et al., 2005).
The lack of political commitment is in large part due to the economic insecurity of each country.
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In 2009, Ecuador’s GDP was 5% for health expenditures, which ranked 140th in the world
(INEC, 2012).
1.5 Pathogenesis of Tuberculosis
Tuberculosis infection takes place when someone inhales droplet nuclei containing
tubercle bacilli that have reached the alveoli in the lungs (CDC Ch2, 2012). Once the droplet
nuclei together with tubercle bacilli are inhaled into the alveoli, the tubercle bacilli multiply
within resident macrophages (CDC Ch2, 2012). Tubercle bacilli enter the bloodstream and
spread throughout the body (CDC Ch2, 2012). This interaction with macrophages begins an
inflammatory response, which includes production of TNF, IL-12, IL-6, and various chemokines
(Ling Lin et al., 2007). These molecules prompt other cells to enter the lungs, including
monocytes that differentiate into macrophages, then neutrophils, and eventually lymphocytes
(Ling Lin et al., 2007). Dendritic cells or specialized antigen-presenting cells can consume M.
tuberculosis, which results in a mature dendritic cell that then makes its way to the regional
lymph nodes (Bhatt et al., 2004; Bodnar et al., 2001). At the lymph nodes, dendritic cells prime
CD4+ and CD8+ T cells specific for Mycobacterium antigens (Lazarevic et al., 2003). The
activated T cells travel back to the lungs and participate in granuloma formation by secreting
cytokines including IFN-y and TNF-α, which activate macrophages (Lazarevic et al., 2003).
Macrophages, specialized immune cells, surround and ingest tubercle bacilli within 2 to 8
weeks (CDC Ch2, 2012). A granuloma or barrier shell is formed when the macrophages
surround the tubercle bacilli so that they are encapsulated (Ling Lin et al., 2007). In one piece, a
granuloma encompasses macrophages, multi-nucleated giant cells, lymphocytes (both CD4+ and
CD8+ T cells, and B cells), neutrophils, and sometimes fibroblasts (Ling Lin et al., 2007). When
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the granuloma forms around the tubercles bacilli, it is known as a latent tuberculosis infection
(LTBI). The granuloma is made from a defense wall of macrophages, epithelial cells, Langhans
giant cells and lymphocytes gather around a center of inflammation. Its function is to isolate
mycobacterium tuberculosis at the place of penetration and thus prevent it from spreading further
(Ling Lin et al., 2007). However, if the immune system gets weaker, the granuloma breaks and
the tubercle bacilli spread out of the shell and multiply quickly (CDC Ch2, 2012). This results in
active TB disease. Granulomas frequently have a necrotic center or caseous necrosis, thus
permitting bacteria to survive within macrophages (Ling Lin et al., 2007). The benefit to the
bacterium is that the granuloma provides shelter until conditions are favorable for growth leading
to potential reactivation (Ling Lin et al., 2007). However, cytokine TNF-α is critical to the
maintenance of the granuloma in that it mediates apoptosis of infected cells so that the
granuloma calcifies and discharges from the body (Ling Lin et al., 2007).
1.6 Latent Tuberculosis Infection and TB Disease
Latent tuberculosis infection [LTBI] arises when a person has inactive, small amounts of
M. tuberculosis bacteria in their body. This is where the bacteria would become encapsulated as
explained in the pathogenesis of tuberculosis. Persons with LTBI do not have TB disease and
cannot spread the infection to others (CDC Ch2, 2012). Latent TB is not considered a TB case.
LTBI takes 2 to 8 weeks after initial TB infection to be diagnosed by a tuberculin skin test (TST)
and/or interferon-gamma release assay (IGRA) (CDC Ch2, 2012). Acid Fast Smear (AFB) and
culture diagnostic methods should be used to collect the body fluid from the site of disease (CDC
Ch2, 2012). In summary, Table 2 describes the differences between LTBI and TB Disease (see
Table 2).
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Overall, only about 10% of infected people become sick with TB (CDC Ch4, 2012). Of
the 10%, 5% will go on to develop active TB disease in the first or second year after developing
the latent form (CDC Ch4, 2012). The other 5% will develop active TB disease later on in their
lives when their immune system becomes compromised due to aging or illness such as
HIV/AIDS, diabetes, chronic renal failure, intravenous drug use, aging or immunosuppressive
therapy used to treat auto-immune diseases such as, rheumatoid arthritis, lupus, etc. (CDC Ch4,
2012).
1.7 Clinical Forms of Tuberculosis
The four clinical manifestations of TB include pulmonary disease, extra-pulmonary
disease, miliary disease, and tuberculosis meningitis. Pulmonary tuberculosis occurs when
Mycobacteria are inhaled. These can traverse the upper respiratory defenses and become
deposited deep in the lung (CDC Ch4, 2012). This primary form of TB has no symptoms and is
more likely to be overcome by the immune system (CDC Ch4, 2012). The early clinical signs
and symptoms of pulmonary TB are often nonspecific, and approximately 5% of active cases
that have complete absence of symptoms. Hematologic symptoms include peripheral blood
leukocyte count and anemia that happens in approximately 10% of patients (Leung et al., 1999).
Cough is the most common manifestation associated with TB. However, it can be nonproductive in the early onset of the disease (Leung et al., 1999). Subsequently, the production of
mucoid or muco-purulent sputum may be produced with time after being infected with TB
(Leung et al, 1999).
Delays in diagnosis are often found among elderly persons (>65 years of age) (Leung et
al., 1999). Elderly persons are less likely to show the common symptoms such as cough,
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hemoptysis, fever, and night sweats in comparison to younger people (Leung et al., 1999). They
may present other symptoms regarding changes in functional capacity, such as chronic fatigue,
cognitive impairment, anorexia, or unexplained low-grade fever (Leung et al., 1999). TB can
also occur in extra-pulmonary sites such as the bones, joints, kidneys, pleura, spine and lymph
nodes. This is known as extra-pulmonary TB. Other sites of TB disease include miliary TB, and
tuberculosis meningitis (CDC Ch4, 2012). Miliary TB is the disseminated hematogenous of
tuberculosis characterized by the appearance of tiny tubercles on one or more organs of the body
(CDC CH4, 2012). It results from tubercle bacilli being spreading through the bloodstream.
Tuberculosis meningitis (TBM) is a central nervous system infection where TB bacteria enter the
membranes and fluid surrounding the brain and spinal cord (Pasco, 2012). Initially the TB
infection begins in the body, typically in the lungs, and then travels into the bloodstream to the
meninges where small abscesses known as microtubercles are formed (Pasco, 2012). When the
micro-tubercles burst, TB meningitis is the outcome (Pasco, 2012).
1.8 Tuberculosis Treatment
The first-line treatment for active TB involves taking a cocktail of 4 drugs for a 6 to 9
month time period: isoniazid (INH), rifampin (RIF), ethambutol (EMB), and pyrazinamide
(PZA) (CDC Treatment, 2003). These drugs are taken for an initial phase of 2 months and then a
continuation phase of 4 or 7 months. Fifty-six doses for eight weeks with the four drugs (INH,
RIF, EMB, PZA) in the initial phase of treatment is necessary for the regimen to be most
effective (CDC Treatment, 2003). The recommended dosage for the continuation phase is INH
and RIF daily for a total of 126 doses in 18 weeks or INH and RIF twice-weekly for a total of 36
doses in 18 weeks (CDC Treatment, 2003). The 4-month continuation phase is used for the large
majority of patients (see Figure 1) (CDC Treatment, 2003).
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Tuberculosis drugs can cause severe side effects, which often make it difficult for patients to
adhere to the treatment (CDC Treatment, 2003). For example, INH side effects include anorexia,
nausea, vomiting, dark urine, icterus, rash, parasthesias on hands and feet, and weakness (CDC
Treatment, 2003). Additional side effects can occur with these drug regimens include hepatitis,
fever, thrombocytopenia, GI upset, and orange colored body fluids (CDC Treatment, 2003).
1.9 Drug Resistance Treatment
Tests to identify TB-resistant strains may take several weeks (Palomino, 2007). Therefore;
treatment depends on how quickly a TB resistant case is identified and whether a drug regimen is
available (Palomino, 2007).
Second line drugs used to combat MDR-TB include but are not limited to fluoroquinolines,
polypeptides, amikacin, kanamycin, and capreomycin for 18 months (CDC Ch4, 2012). Less
than 3% of the world’s MDR-TB patients obtain treatment due to the complex and high cost of
proper treatment. Resource-constrained countries will be challenged to supply proper treatment
for their MDR-TB patients since it is thousands of times as expensive as that of regular treatment
in some regions (TB Alliance, 2012).
Extensively Drug-Resistant TB [XDR-TB], the most severe type of TB-drug resistance, is
defined as being resistant to isoniazid and rifampin, any fluoroquinolone, and one of three
injectable second line drugs (see Figure 4) (CDC Ch4, 2012). It is resistant to both first and
second line drugs leaving patients with options to treatment regimens containing toxic drugs,
which are very expensive and not very effective (CDC Ch4, 2012). The WHO estimates that 5%
of MDR-TB cases are XDR-TB. According to the TB Alliance, 70% of XDR-TB patients die
within a month of diagnosis (TB Alliance, 2012).
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Recently, strains of Totally-Resistant Tuberculosis [TDR-TB] have been identified in India,
those strains are untreatable by any currently available drug (Huffington Post, 2012). It has also
been reported that TDR-TB is highly contagious (Huffington Post, 2012). A person with this
strain encounters a 100% mortality rate with a probability of spreading the infection to those in
close proximity (Huffington Post, 2012).
1.10 Laboratory Diagnostic Methods for TB
Sputum smear and culture are two separate tests used to identify TB in a patient. Sputum
smear involves the microscopic examination of a fluorochrome stain of Mycobacteria (WHO
Clinical, 2012). On the other-hand, the culture method is the inoculation of Mycobacteria onto
the Lowenstein-Jensen (L-J) media.59 It is incubated at 37°C for up to eight (8) weeks to detect
growth or no growth during the incubation period (WHO Clinical, 2012). The culture test is
observed on the 4th and 8th week. Drug Susceptibility Testing (DST) determines the ability of the
four primary anti-tuberculosis drugs to inhibit the growth of Mycobacterium tuberculosis
complex in a broth, which uses concentrations of drugs tested (WHO Clinical, 2012). DST
allows the physician to prescribe the correct drug regimen for positive TB patients. It also reveals
drug resistance in patients (WHO Clinical, 2012).
Suspected cases of TB are often confirmed through using sputum smear in resourceconstrained countries, such as those in Latin America. Culture is used to diagnosis TB in the
urinary tract, TB reactivation, or to determine drug resistant TB. The gold-reference standard is
culture for diagnosing active TB in low-income countries. However, the sputum smear
microscopy is used more often because it is rapid, specific, inexpensive, and useful in identifying
highly contagious people (WHO Policy, 2011). Different from saliva which is sputum produced
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by phlegm that is coughed up from the lungs. Sputum smear microscopy [SSM] uses direct
smear microscopy to analyze sputum by staining the bacterial cell wall of Mycobacterium
tuberculosis (PAHO, 2005). The sputum smear microscopy is not very sensitive (WHO Policy,
2011). False negatives occur predominantly in SSM because the measurement by the technician
is subjective, and/or when the number of mycobacteria in sputum is low or below the limit of
detection by SSM. A meta-analysis conducted by Steingart and associates resulted in 54%
detection by conventional microscopy (Steingart et al., 2006). Other studies, such as Swai et al
(2011) list the specificity of SSM as 75% (Steingart et al., 2006).
Other limitations of microscopy are detecting TB in children and HIV co-infected
persons (WHO, 2011). Among 160 patients who were HIV-positive in the Peruvian Hospital
Nacional Dos de Mayo, the sputum smear test detected only 8 of 14 cases of TB indicating areas
of co-morbidities to be problematic for this standard test in Latin America (Vargas et al, 2005).
The gold standard technique (culture) is a more desirable option in identifying TB due to
its high sensitivity in detecting TB in low bacterial concentrations, co-morbidities, and in drug
resistant cases (Palomino et al., 2007). The limitations of the culture method include a slower
diagnostic time, higher costs, and the need for more lab infrastructure (Palomino et al., 2007).
The culture technique involves growing live mycobacteria on a medium plate, which may take
up to two to eight weeks for results (Palomino et al, 2007). The Lowenstein-Jensen Medium is
the most widely used growth medium when using tuberculosis culture because of its high
reported specificity (97%) and sensitivity (82%) (Palomino et al, 2007). Unfortunately, the high
cost of the culture method and lack of necessary lab infrastructure limit this in low resource,
developing countries (Palomino et al., 2007).
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Predominantly in resource-constrained settings, the laboratory evaluation of sputum with
culture followed by drug susceptibility testing is based on solid media (Palomino et al., 2007).
The method is fairly inexpensive and the results for confirming a positive drug-resistant TB
status may take up to two (2) months or longer (Palomino et al., 2007). Diagnostic delays in
confirmation also delay immediate treatment for the patient. Liquid-based media, such as
Mycobacterium Growth Indicator Tube, reduces diagnostic time confirmation from months to
weeks (Palomino et al, 2007). However, the liquid-based media requires extensive resources,
supplies, and equipment that may not be sustainable in limited resource-constrained settings.
The World Health Organization guidelines for laboratory capacity are 1 culture lab for
every 5 million persons and 1 drug-susceptibility lab for every 10 million persons (WHO, 2011).
The table describes the number of laboratories providing tuberculosis diagnostic services
reported annually by countries to WHO using a web-based data collection system (WHO Global
Observatory, 2013) (see Table 3). In Table 3, the distinction in infrastructure is very clear
between US laboratory infrastructure and that of Latin American countries. Significant
differences are the lack of culture labs and DST labs in Latin America when compared to the US
(see Table 3). However, the Latin American countries show more SSM labs than the US (0.6).
For example, Mexico does not have the recommended infrastructure for drug-susceptible testing:
0.7 labs per 10 million. This may be a barrier in detecting drug-resistance in the population. The
population-level impact would be if there is not proper detection then there will be a rise in
transmission.
1.11 The Context of TB in Ecuador
Ecuador is a clear representation of many Latin American countries in understanding the
complex problems in controlling tuberculosis. Ecuador ranks 60th out of 212 tuberculosis17	
  
	
  
	
  

prevalent countries in the world (see Table 1) (WHO Global, 2012). On average in 2012, the
incidence for TB in Ecuador was 59/100,000 inhabitants (WHO Ecuador, 2011). This is a
substantial increase for incidence reported in 2003: 44.95/100,000 inhabitants (Mangan 2008).
Ecuador is one of the top 10 countries in the Americas for TB Incidence (PAHO, 2012). Cases of
tuberculosis in Ecuador were estimated to be 98 per 100,000 persons in 2011 (WHO Ecuador,
2011). By law in Ecuador, TB is a notifiable disease and must be reported to the Ministerio de
Salud Publica (Ministry of Public Health). Actual prevalence and incidence rates are most likely
higher than indicated since the data is collected by the Ministry using passive rather than active
surveillance. Ecuador like most other countries did not have an active surveillance of TB and
other diseases (Ministerio de Salud Publica, 2011). Another issue with TB control and prevention
is that Ecuador continues to use the sputum method to diagnose TB rather than using culture as
standard. Treatment success rate for new smear-positive cases was 78% (WHO Ecuador, 2011).
In prior years, there were issues on inadequate diagnosis, which is supported by the Health
Ministry of Ecuador’s statement that TB cases were not being effectively detected (Ministerio de
Salud Publica, 2011). The smear positive case notifications for 2012 were 3,856 and 285 for
smear-negative cases (WHO Ecuador, 2011).
Findings in a preliminary sample survey of resistance in 1986-1990 reveal that Ecuador,
Haiti, and the Dominical Republic had the highest rates of drug-resistance in the Americas
region (PAHO, 2007). Reported cases of MDR in pulmonary TB in Ecuador rose to 190 cases
per 100,000 (WHO Ecuador, 2011). Additionally, there were 160 retreatment cases, which
almost is in line with new cases a year (WHO Ecuador, 2011). The growing number of
retreatment cases may be a potential sign in the rise of drug resistance. In a regional study by
PAHO, Ecuador has an estimated 26% of retreatment cases for pulmonary TB for MDR-TB
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(PAHO, 2012). This ranks Ecuador as the 4th most prevalent country in Latin America for
estimated MDR-TB cases in pulmonary TB (PAHO, 2012). At least one case of XDR-TB was
reported in Ecuador by the end of 2011(PAHO, 2012).
Although there is limited data on the prevalence and incidence of primary tuberculosis in
Quito, there is available evidence for other areas in Ecuador. In an indigenous province,
Cotopaxi, 47% of study participants had active pulmonary TB recorded using the sputum
diagnostic method (Romero-Sandoval et al., 2007). Of the smear positive cases, 29.5% gave a
history of prior active TB (Romero-Sandoval et al., 2007). A study of two clinics in Quito,
Ecuador (June 1989 to March 1996) showed primary drug resistance was identified in 24% of
patients (Mertz et al., 2000). However, these patients did not appear to be representative of the
general population in Quito since they were private medical patients. The results for TB drug
resistance in the study’s patients were isoniazid (14.2%) and rifampin (11.8%) (Mertz et al.,
2000).
Quito’s population is composed of over 1,600,000 individuals: 49.6% men and 50.4%
women (INEC, 2010). The average age of the population in Quito for both men and women is 29
years of age indicating a relatively young adult population (INEC, 2012). The identity of the
Quito population is as follows: Mestizo (82.8%), White (6.7%), Afro-Ecuadorian (4.7%), and
Indigenous (4.1%) (INEC, 2010). The predominant religion is Roman Catholic (95%) (Mangan,
2008). A National Survey revealed the country has a 5% unemployment rate and 16.4% of the
population lives under the poverty line for 2012 (INEC, 2012). Quito’s unemployment rate and
poverty level (9%) is below the national rate (INEC, 2012).
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The Ministry of Public Health primarily provides health services in Quito, even though
both private and public sectors exist (INEC, 2012). The Ministry of Health covers 80% of the
population in the city, 10% by the Ecuadorian Social Security Institute, and 10% by other
agencies (INEC, 2012). According to INEC, 46.1% of people in Quito have public insurance and
19.1% have private insurance (INEC, 2010).
A study by Armijos et al explores the demographics (n=212) in Quito of some of the
present study’s participants on exploring knowledge, beliefs, perceptions, and attitudes about
tuberculosis (see Table 4) (Armijos et al., 2008).
1.12 Location
Quito is the capital of Ecuador located in an Andean valley between the Pichincha Volcano and
the Itchimbía Hills (CIA, 2012). The weather is an average maximum temperature of 21 degrees
Celsius and minimum of 8 degrees Celsius (CIA, 2012).	
  	
  
1.13 Study Rationale
The proposed study compared the diagnostic properties of the sputum smear with the
culture method considered to be the diagnostic gold standard for TB. It is important to have a
diagnostic method that is highly sensitive in order to have effective control of TB. The problem
is that many low and middle-income countries continue use the sputum measurement as the
standard despite its documented low sensitivity and inability to detect drug-resistant TB strains.
The principal rationale for the study was to validate the need to replace the SSM with the gold
standard (culture) in order to control and prevent existing TB and TB resistance in Latin
America. Other studies already show SSM as having low sensitivity, which leaves a significant
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number of people undetected and able to transmit TB. This study evaluated this problem in
patients and defined the public health impact.	
  	
  
Another reason to assess the diagnostic performance of sputum smear is because it does
not appear to consistently detect primary resistance and TB in co-morbidities. Since SSM is not
an effective tool in detecting drug resistant strains, it was important to describe the levels of
primary drug resistance, multi-drug-resistance, and susceptibility the population. The study was
able to describe the TB situation in a public health facility in Quito from a sample of referred
suspected patients.
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Chapter 2: Major Aims and Objectives
The major goal of the proposed study was to evaluate the sensitivity of sputum smear
microscopy compared to culture, the gold standard, as a primary technique for diagnosing
pulmonary TB in study subjects. Another goal was to assess the prevalence of primary resistance
to antibiotics used to treat TB.
2.1 Study Aims
Study Aim 1: To compare the sensitivity and specificity of SSM and culture.
Study Aim 2: To determine the prevalence of pulmonary drug-resistant TB.
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Chapter 3: Hypothesis
Hypothesis 1: Because of its documented low-sensitivity, sputum smear microscopy will have
more false-negatives than the culture method.

	
  

Hypothesis 2: Frequency of pulmonary drug-resistant TB will be significantly high in the study
sample because of the documented high prevalence of drug resistance and retreatment cases.
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Chapter 4: Methods and Materials
4.1 Human Subjects
The Ministry of Public Health in Ecuador [Ministerio de Salud Publica- MSP] has
primary responsibility for TB control in Ecuador. The primary role of the tuberculosis
department within the INHLIP’s Microbiology Department is to diagnosis. TB and maintain TB
treatment at MSP locations. The study participants were referred by health care centers to the
National Institute for Hygiene “Leopoldo Izquieta Perez” [Instituto Nacional “Leopoldo Izquieta
Perez”] (INHLIP) in Quito, Ecuador. Health care professionals in Ecuador have the
responsibility to refer individuals who exhibit TB characteristic respiratory and other symptoms
(Armijos et al., 2008). The present study collected data of persons who were referred to the
INHLIP-Quito as suspected cases of tuberculosis. Suspected cases of TB were defined as
persons having the signs and symptoms of active disease.
A convenience sample of 1487 persons was referred to the INHLIP-Quito from 19992000. The INHLIP-Quito collected samples for SSM, culture, and DST for each referred patient
by lab technician, Bernadette Ulloa.
4.2 Study Design
The cross-sectional study used data collected at the TB diagnostic lab, Instituto Nacional
de Higiene “Leopoldo Izquieta Perez” [INHLIP-Quito], from 1487 patients. Sputum samples
were collected from each patient and analyzed during a 12-month period (January 1999- August
2000) at the INHLIP-Quito. The sputum, culture, and DST tests were analyzed by the
Tuberculosis Department in INHLIP-Quito led by the Director Dr. Rodrigo X. Armijos and lab
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technician Bernadette Ulloa. Primary resistance was also tested using drug susceptibility testing
for isoniazid, rifampicin, ethambutol, pyrizanamide, and ethionamide.
4.3 Data Collection
The socio-demographic characteristics collected from the study participants include age
and gender. Laboratory tests used to detect TB were sputum smear microscopy and culture.
Three samples were retained for sputum microscopy and one for culture testing. The culture
samples were grown and observed at the 4th and 8th week at the INHLIP-Quito. Each participant
provided sputum for the SSM that was compared to the culture growth of the same sample.
4.4 Sputum Smear Microscopy
The tuberculosis case definition for a sputum smear is one positive smear or one or more
acid-fast bacillus in at least 100 microscopic fields (CDC Ch4, 2012). For diagnostic purposes,
the patients with suspected TB arrived in the morning to have three consecutive sputum
specimens collected. Patients were requested to produce a sputum specimen into a sterile
container (CDC Ch4, 2012). The lab technician then prepared the specimen by spreading the
sputum specimen on a glass side. The decolorizing acid was then applied to the sputum glass
slide in order to stain the bacterial cell wall of Mycobacterium tuberculosis (Palomino et al.,
2007). Therefore, a patient was positive for tuberculosis when a red stain appeared due to the
Mycobacteria. The benefit of the Z-N stain method was that the smears could be scanned
efficiently under low magnification (WHO Clinical, 2012). This process was repeated two more
times for a total of three Acid Fast Bacilli smears.
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In slide reporting, the number of bacilli detected in the smear reflected the severity of the
disease and patient infectivity (WHO Clinical, 2012). The table below shows the standard
method of how bacilli were reported using 1000 x magnification (see Table 5). 	
  
Laboratory technicians analyzed all three sputum samples of potential TB cases. They
recorded the result of each sputum sample with a laboratory reference number for the registry
and on the sputum request form (WHO Clinical, 2012). In order to categorize a patient as smearpositive or smear negative, results from more than one smear were needed (see Table 6).
4.5 Culture Method
The tuberculosis case definition for culture was identified through colony morphology,
growth at different temperature times, and growth on para-nitrobenzoic acid Lowenstein-Jensen
slopes (WHO Clinical, 2012). After the sputum sample was collected, it was decontaminated
using sodium hydroxide to eliminate micro-organisms from the normal flora (Palomino et al.,
2007). It was then spread on a culture medium plate containing Lowenstein-Jensen and placed in
an incubator at 37 degrees Celsius (WHO Clinical, 2012). The growth and identification of
tubercle bacilli or other mycobacteria on culture plate was observed after the 4th and 8th week. A
positive culture was identified when non-pigmented colonies appeared (Palomino et al., 2007). If
no colonies were present, it was a negative TB case.	
  
4.6 Drug Susceptibility Testing
Primary drug resistance was defined as resistance to one anti-tuberculosis drug (CDC
Ch2, 2012). Drug susceptibility testing was done using an indirect proportion method on
Middlebrook 7H10 agar containing concentrations of 0.2-mg/L isoniazid, 30-g/L rifampicin, 2mg/L ethambutol, 5mg/L pyrizanamide, and 20-mg/L ethionamide (Pinto et al., 2011; WHO
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Clinical, 2012). Antibiotic concentrations were placed in five-quadrant petri dish at 35 degrees
Celsius (Pinto et al., 2011; WHO Clinical, 2012). The test required 1 month to complete (CDC)
(Pinto et al., 2011). Growth on the control medium was compared to the growth on the drugcontaining medium to determine susceptibility or resistance. The test was considered positive for
resistance if >1% colony count was present in a quadrant with antibiotic (WHO Clinical, 2012;
Van Rie et al., 2000).
4.7 Data Analysis
The data was entered in the SPSS management and statistical analysis system [SPSS,
Chicago, Illinois, U.S.A.; version 17] to find descriptive data. The plan was to calculate the
sensitivity, specificity, positive predictive value, and negative predictive value of sputum smear
and culture findings using the set of TB case definitions as the reference standard diagnosis (see
Figure 2). The analysis also determined the sensitivity and false specificity resulted by the
diagnostic tests in order to quantify the effectiveness and validity. The sensitivity of a diagnostic
test is defined as the ability to correctly identify those persons who have the disease (Gordis,
2009). Specificity is defined as those persons who are correctly identified in not having the
disease (Gordis, 2009). The positive and negative predictive values were calculated to enhance
the physician’s ability to determine a correct diagnosis. The predictive value is affected by two
characteristics, the prevalence of the disease in the population tested and when the disease is
infrequent, the specificity of the test being used (Gordis, 2009). Positive predictive value is
defined as the probability the patient has the disease when given a positive test result (Gordis,
2009). Negative predictive value is the probability that the patient does not have the disease
given a negative result (Gordis, 2009). Using SPSS, the analysis evaluated the frequencies of
primary resistance discovered within the five drug treatments: pyrazinamide, ethambutol,
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isoniazid, and rifampicin. The design for determining the sensitivity, specificity, NPV, PPV is
shown in Figure 5.
A sub-analysis was also calculated for the sputum smear test in regards to the added
diagnostic value for the second and third sputum test. The analysis calculated the patients’
positive in the second sputum test that were not confirmed by the first sputum smear (Aziz et al.,
2005). The added value was also calculated for patients who were confirmed in the third sputum
smear that were not accounted for in the first and second sputum smears (Aziz et al., 2005). The
added diagnostic value was also used for culture at 8 weeks when compared to culture at 4
weeks. The importance of the sub-analysis was to find the incremental yield of each specimen
test to determine the value.
For M. tuberculosis, the susceptibility testing critical concentration is defined as the lowest
concentration of drug that will inhibit 95% (90% for pyrazinamide) of wild strains of M.
tuberculosis that have never been exposed to drugs (Palomino et al., 2007). While at the same
time not inhibiting clinical strains of M. tuberculosis that are considered to be resistant (e.g.
patients not responding to therapy) (Palomino et al., 2007). Resistance was important to
determine in the sample population because it will unveiled the prevalence of drug-resistance
(single or multi).
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Chapter 5: Results
From January 1999 to April 2000, we had 1487 patients. The sample population was 53% female
(n= 798) and 46% male (n= 689) (see Table 7). The median age of the sample was 42 years of
age from a range of 3 to 94 years old.
In sputum smear sample 1 and culture at 4 weeks, the sensitivity is 58% meaning that
almost 4 out of 10 persons are incorrectly identified as negative for pulmonary tuberculosis (see
Table 10). The positive predictive value or the probability that patients had the disease is 79%.
The negative predictive value is 95%.
In sputum smear sample 1 with culture at 8 weeks, the sensitivity of the test was 44%.
Culture at 8 weeks (44%) did not significantly detect more cases than culture at 4 weeks (58%)
for the 1st test (see Table 8). Moreover, the specificity of the test is 99% indicating that almost all
persons who were not diseased were identified as negative by the test. Positive predictive value
is 89%. The probability is 90% that the patient does not have the disease or negative predictive
value.
The sputum smear sample 2 with culture at 4 weeks shows a sensitivity of 65%, which is
7-20% more than the sensitivity reported in the sputum sample 1 diagnostic exams. The
specificity of the test at 4 weeks is 97%. The positive predictive value dropped to 71% compared
to sputum smear 1 at 8 weeks (see Table 8). The negative predictive value stayed significantly
strong (95%).
The sputum smear test 2 with culture at 8 weeks has a sensitivity of 58%. Specificity of
the test was 99%. The positive predictive value went up to 93% with culture at 8 weeks revealing
a difference of 22% when compared to sputum test 2/culture at 4 weeks (see Table 8). The
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negative predictive value decreased 2% when compared to culture at 4 weeks. The negative
predictive value is still significantly strong (92%) in this sample size.
Sputum diagnosis 3 and culture at 4 weeks had sensitivity reported as 68%. The
specificity (97%) was the same as that of sputum diagnosis 2 confirmed by culture at 4 weeks.
The positive predictive value (72%) and negative predictive value (96%) were strong.
Sensitivity for sputum diagnosis 3 and culture at 8 weeks is 56%. Both the positive
predictive value (96%) and negative predictive value (97%) increased from culture at 4 weeks.
Averages for the three sputum samples and culture growths showed that the sensitivity
was 58% and specificity as 97.8%. Both the NPV (94.1%) and PPV (83.3%) remained strong for
the sample size.
In comparing the 1st sputum sample to the 2nd and 3rd, it was found that:
•

8% Diagnostic Added Value for Sputum 2 (See Table 9)

•

1% Diagnostic Added Value for Sputum 3 (See Table 9)

This is evidence that the 3rd Sputum Sample does not have a significant value in the diagnosis
since it detects an added value of 1% (see Table 11). The 1st sputum sample detects the majority
of positive cases for TB.
The added diagnostic value of culture at 8 weeks is 44%. This implies that the reason for
an 8-week TB culture is because M. tuberculosis grows very slow (see Table 9) (Beste et al.,
2009). The ability of TB bacteria to continue in an inactive state with immune clearance is an
important obstacle in TB control (Beste et al, 2009).
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Ten-percent (10%) of the 1487 participants were selected randomly for drug
susceptibility testing. Sixty-eight participants presented some form of resistance to the TB drugs.
Out of these, 68 participants, 9% were resistant to 1 drug and 24% were multi-drug resistant (see
Figure 3). In analyzing the results for patients, isoniazid was the most predominant drug reported
for persons exhibiting resistance to only 1 drug (n=8) (see Table 10). A total of 18 participants
were tested positive for resistance to 1 drug.
Multi-drug resistance was tremendous in this sample size accounting for 24% of
participants. Resistance to Isoniazid and Rifampicin was predominant in the sample (n=16).
Isoniazid-Rifampicin Resistance (7.6%) was ranked at the top in multi-drug resistance (see Table
11). Isoniazid and Rifampicin accounted for 24.6% each in total (single and multi-drug
resistance). This may be an indication that Isoniazid is easily accessible and being used for
medicating non-tuberculosis infections (Caminero et al., 2007). Out of the 50 multi-drug
resistant cases, 4 were completely resistant to all the drugs tested (Isoniazid, Rifampicin,
Pyrizinamide, Ethambutol, Ethionamide). Moreover, 143 of the 211 participants did not have
drug resistance.
After reviewing the resistance among common drug treatments, it is evident the drugs
persons are most resistant to are isoniazid and rifampicin. There is a higher occurrence of
resistance to antibiotics in males than females in all three comparisons: single, multi, and total
(see Tables 10, 11, 12).	
  In Table 15, we display the susceptibility patterns of the patients. Most
susceptibility lies with isoniazid (20.3%) and ethambutol (25.1%) (see Table 13).
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Chapter 6: Discussion
The average sensitivity of 58.1% of the sputum samples in comparison to culture samples
shows that there is a significant gap in patients who are being diagnosed with TB. This means
that approximately 4 out of 10 positive TB cases are being missed when the sputum smear
method is used as the standardized method of diagnosis in suspected cases. The average
specificity (97.8%) in the sample displays that 2% of cases are not being identified properly as
true negative cases. The average NPV (94.1%) and PPV (83.3%) are strong in the sample, which
is a characteristic of the sputum smear test (WHO Guidance, 2010).
Currently, Ecuador, as well as other Latin American countries, does not use the culture
method as the standardized method of testing. In a study by Romero-Sandoval and associates, the
sputum diagnostic method detected 47% of TB cases among participants in an Ecuadorian
province (Romero-Sandoval et al.,2007). A meta-analysis also supports the low sensitivity of the
sputum test reporting an overall 54% sensitivity and 75% specificity (Steingart et al., 2006; Swai
et al., 2011). Our study reported an average sensitivity of 58.1%, which is very similar to the
findings in the meta-analysis. However, the average specificity of our findings was much higher
(97.8%). Based on the results of this study, it is suggested that culture should be used. It already
is the gold standard of diagnosing TB in all suspected patients. Assael and associates supports
this issue in that 80% of actual cases had smear-negative results in Mexico using only sputum as
a TB diagnostic tool (Assael et al., 2013). This translates to 8 out of 10 patients with TB being
missed while using SSM. The public health implications for using sputum test as a gold standard
are patient misdiagnosis, endangering the public to TB transmission, and creating an ample
environment for potential drug-resistance. If a diagnosis delivers a false negative, there will be a
long-term population-level-impact in TB transmission: LTBI or Active.
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In examining the value that sputum sample 2 and 3 add in detecting TB, it was found that
the 3rd sputum sample does not have a added diagnostic value since it detects only 1%. The 1st
sputum sample seems to be the first exam that detects the majority of positive cases whilst
sputum sample 2 has an added value of 8%. The findings support a subgroup analysis by Mase
and associates showing that the third sputum test had a low added value of 2.3% (Mase et al.,
2007). The results support a current WHO expert consultation on TB case detection
recommending the collection and examination of two sputum smears for the diagnosis of
pulmonary tuberculosis (Aziz et al., 2005). A study demonstrating that two sputum smears may
be adequate for primary evaluation of HIV infected TB suspected patients found the diagnostic
yield of 3rd sputum to be very low (only 6.3%) (Marjani et al., 2012). Sensitivity in sputum
smears increased from 67% with 1 sputum collected to 71% (second) and 72% (third) sputum
specimens (Leonard et al., 2005). The examination of only two smears could therefore alleviate
the workload of laboratories, particularly in countries with a high microscopy workload, by onethird.60 It is also expected that the microscopic analysis of two sputum smear samples will
improve case findings through enhanced quality of service, decreased time for diagnosis and
initiation of treatment, and decreased number of patients dropping out of the diagnostic pathway
(Aziz et al., 2005). In addition, patients will spend less time at the diagnostic facility, which may
save expenses for them and improve infection control measures.
Using culture as the primary method of diagnosis shows tremendous value. In comparing,
culture from the 4th to the 8th week, it was reported that there was an added value of 44%. There
are TB strains that grow slow which are why it is necessary to wait until 8 weeks (Palomino et
al., 2007). In general, mycobacterium grows particularly slow (Beste et al., 2009). For this reason
as well as the fact that TB bacteria can remain in a refractory state to bypass the immune system
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continues to remain a tremendous challenge in preventing TB (Beste et al., 2009). This analysis
supports the theme that culture at 8 weeks adds positive cases of TB.
The susceptibility patterns of the patients falls with isoniazid 43 (20.3%), ethambutol 53
(25.1%), and ethionamide 47 (22.2%). In Asaad and associates, susceptibility was found most in
ethambutol 66 (97.1%), streptomycin, rifampicin 52 (76.2%) (Asaad et al., 2012). The most
common similarity is that most of the susceptibility was found in ethionamide for both sample
populations (Asaad et al., 2012). Ethionamide is one of the most frequently used and efficacious
second-line drugs (Asaad et al., 2007). In total, resistance in this study amounted to 32.2% of 211
patients. Of the 32.3% resistance: 8.5% was single-drug resistance and 23.7% was multi-drug
resistance. Within single-drug resistance, Isoniazid was the drug that showed the most resistance
(3.8%). Moreover, in multi-drug resistance, Isoniazid with Rifampicin had the most reported
drug resistance (7.9%). In finding the frequency for resistance to each drug, it was also found
that both Isoniazid and Rifampicin each had 24.6% of the reported resistance. What this means is
that high levels of isoniazid resistance show that new TB patients receive rifampicin, ethambutol,
isoniazid as an alternative therapy to isoniazid and rifampicin in the continuation phase (Asaad et
al., 2007). For the reason of high frequencies of rifampicin and isoniazid resistance is because the
patients self-administer the first-line defense drugs.67 Patients may not know how to properly
medicate themselves creating long-term results in transmissible resistant isolates. In Baliza and
associates, rifampicin and isoniazid resistance was highly reported in Brazil (Baliza et al., 2008).
Resistance to isoniazid and rifampicin, or multidrug resistance, occurred in 24 (14%) of the cases
(Baliza et al., 2008). The outcome was reported to be from inappropriate or irregular drug supply
and/or to non-adherence to treatment, therefore; favoring conditions for mutated Mycobacterium
tuberculosis strains (Baliza et al., 2008). Patients who abandon treatment for TB have five times
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greater risk of progressing to MDR-TB.67 The study’s results in drug-resistance are parallel to
drug resistance in Southwestern Saudia Arabia (Asaad et al., 2012). Resistance was primarily
found in Isoniazid (33.8%) and Rifampicin (23.5%) (Asaad et al., 2012). Another big problem in
developing countries is that rifampicin is also used to treat non-tuberculosis bacterial infection
(Caminero et al., 2010). Armijos and associates describes the sub-population as reporting that
51% used MSP and private pharmacies to obtain treatment (Armijos et al., 2008). This practice
will promote the development of M. Tuberculosis resistance to rifampicin. Hang and associates
also demonstrates similar results to Isoniazid resistance along with Streptomycin resistance in
more than a quarter of TB patients without treatment history in Hanoi, Vietnam (Hang et al.,
2013). Transmission of isoniazid-resistant TB should be carefully monitored to prevent
transmission to drug resistant strains (Hang et al., 2013).
Another cause of primary TB resistance among the general population is co-morbidities,
specifically diabetes. In Fisher-Hoch and associates, patients were examined along the USMexico border to find that 161/2878 (5.6%) patients had MDR TB (resistance to rifampin and
isoniazid): Texas 49/1442 (3.4%) and Mexico 112/1436 (7.8%) (Fisher-Hoch et al., 2008). In
Texas and Mexico, MDR TB was significantly associated with T2DM after being adjusted for
age, gender, drug and alcohol abuse, HIV infection and history of previous episode of TB
(Fisher-Hoch et al., 2008).This alarming situation demonstrates the failure of a presence of an
Anti-Tuberculosis Drug Resistance Surveillance system in place. The treatment success rate for
MDR-TB is low, only 6 to 59% (WHO, 2011).
6.1 Study Strengths and Limitations
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The advantage of recruiting the sample population by convenience sampling is it takes less time
to fill the quota without participant requirements, such as age requirements. The participants
were not turned away because there were no requirements to enter the study. The cross-sectional
study design is useful for diseases like tuberculosis that have long inductions or latent periods.
The study is able to compare the effectiveness of diagnosing through sputum smears and culture
samples to detect primary tuberculosis and primary resistance. With this information, we can
support a standard of reference for diagnosing tuberculosis globally. Additionally, mycobacterial
cultures provide a definitive diagnosis of TB, even increasing detection to 30-50% of new cases
and detecting TB before it becomes infectious (Palomino et al., 2007). Also, culture isolates can
be used for drug susceptibility testing (Palomino et al., 2007). In turn, we can measure primary
resistance in this sample effectively with the culture measure.
Since convenience sampling was used to recruit subjects in the study, the results may not
be representative of the population. The study sample recruited from the INHLIP by health
centers. For that reason, the results cannot be applied to Quito, Ecuador entirely but instead
people who attend or who can afford to go to the INHLIP or surrounding health centers. The
results may be highly biased under these circumstances. Another disadvantage to the study
design is losing participants to follow-up. For example, participants in the sputum test are
required to give three sputum smears with a 24-hour time interval for each one. Clearly, some
participants abandoned the study before coming back for the second and third sputum smears. A
significant dropout rate may diminish the impact of the study. The lack of demographic data and
co-morbidity status prevented the ability to describe characteristics of the patients or associated
TB risks.
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For cross-sectional studies, the downside is the population is not being followed for
disease outcome but instead looking at a snapshot single point in time. Clinically, sputum smear
microscopy cannot distinguish M. tuberculosis from drug resistant strains. The Mycobacterium
culture is 82% effective, not 100% sensitive due to decontamination methods in the process that
are sometimes harmful to the mycobacteria (WHO Clinical, 2012). Consequently, good
laboratory expertise runs a delicate equilibrium between the yield of Mycobacterium and
contamination by other micro-organisms (WHO Clinical, 2012). SSM and culture methods are
considerably dependent on the handling of laboratory technicians that may cause error. A clear
diagnosis is dependent on the precision and training of the lab technician of the study, which
cannot be assessed.
6.2 Recommendations
It is highly recommended that Ecuador and countries in Latin America use culture as the
gold standard method for detecting TB to reduce the possibility of false-negatives. Further
studies need to be elicited to determine demographic and clinical backgrounds of patients to
identify potential relationships in smear results. For sputum samples, the recommendation is to
use two sputum smears when diagnosing. This is because the third sputum sample only gives an
additional value of 1%. We can therefore deduce that using the third sputum sample only
increases the workload for technicians and wastes diagnostic material. Finally, the significant
resistance to Isoniazid and Rifampicin is an important constraint in implementing control
measures and developing successful treatment plans. It is recommended that further studies be
used to monitor and evaluation countries’ implementation of TB Surveillance Programs. The
WHO has also recommended using isoniazid and rifampicin for four months instead of the 6month continuation phase using rifampicin, isoniazid, and ethambutol (WHO Policy, 2012). In
37	
  
	
  
	
  

return, this will diminish the number of relapses or failures and preserve patient and national
program resources (WHO Policy, 2012). In response to the results, there should be an optimal
treatment regimen of drug susceptibility tests and intensive monitoring of treatment (Hang et al.,
2013). This would minimize further development of drug resistance strains.
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Figure 1. Treatment Algorithm for Tuberculosisa	
  

a

Source from Centers of Disease and Control40
Patients in whom tuberculosis is proved or strongly suspected should have treatment initiated with isoniazid,
rifampin, pyrazinamide, and ethambutol for the initial 2 months. A repeat smear and culture should be performed
when 2 months of treatment has been completed. If cavities were seen on the initial chest radiograph or the acid-fast
smear is positive at completion of 2 months of treatment, the continuation phase of treatment should consist of
isoniazid and rifampin daily or twice weekly for 2 months to complete a total of 6 months of treatment. If cavitation
was present on the initial chest radiograph and the culture at the time of completion of 2 months of therapy is positive,
the continuation phase should be lengthened to 7 months (total of 9 months of treatment). If the patient has HIV
infection and the CD4+ cell count is <100/µl, the continuation phase should consist of daily or three times weekly
isoniazid and rifampin. In HIV-uninfected patients having no cavitation on chest radiograph and negative acid-fast
smears at completion of 2 months of treatment, the continuation phase may consist of either once weekly isoniazid
and rifapentine, or daily or twice weekly isoniazid and rifampin, to complete at total of 6 months (bottom). Patients
receiving isoniazid and rifapentine, and whose 2-month cultures are positive, should have treatment extended by an
additional 3 months (total of 9 months).
*
EMB may be discontinued when results of drug susceptibility testing indicate no drug resistance.
ϯ
PZA may be discontinued after it has been taken for 2 months (56 doses).
±
RPT should not be used in HIV-infected patients with tuberculosis or in patients with extrapulmonary tuberculosis
§
Therapy should be extended to 9 months if 2-month culture is positive. CXR = chest radiograph; EMB = ethambutol;
INH = isoniazid; PZA – pyrazinamide; RIF = rifampin; RPT = rifapentine.
b

a

Adapted from Centers of Disease and Control29
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Figure 2. Analytical Design for Comparing Sample Test vs. Gold Standarda
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Adapted from Gordis L.67

Figure 3. Diagram of Drug-Resistance by Sample Size (n=211)
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Figure 4. Participants with Pulmonary Tuberculosis (Sputum Diagnosis 1 as confirmed by Culture at 4
weeks)
Condition	
  Positive	
  

Condition	
  Negative	
  

Test	
  
Outcome	
  
Positive	
  

True	
  Positive	
  

False	
  Positive	
  

26	
  

7	
  

Test	
  
Outcome	
  
Negative	
  

False	
  Negative	
  

True	
  Negative	
  

18	
  

316	
  

Sensitivity	
  

Specificity	
  

=TP/(TP+FN)	
  

=TN/(FP+TN)	
  

=26/(26+19)	
  

=316/(18+316)	
  

≈58%	
  

≈95%	
  

54	
  
	
  
	
  

Positive	
  Predictive	
  Value	
  
=TP/(TP+FP)	
  
=26/(26+7)	
  
≈79%	
  
Negative	
  Predictive	
  Value	
  
=TN/(FN+TN)	
  
=316/(18+316)	
  
≈95%	
  

Figure 5. Participants with Pulmonary Tuberculosis (Sputum Diagnosis 1 as confirmed by Culture at 8
weeks)
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Figure 6. Participants with Pulmonary Tuberculosis (Sputum Diagnosis 2 as confirmed by Culture at 4
weeks)
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Figure 7. Participants with Pulmonary Tuberculosis (Sputum Diagnosis 2 as confirmed by Culture at 8
weeks)
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Figure 8. Participants with Pulmonary Tuberculosis (Sputum Diagnosis 3 as confirmed by Culture at 4
weeks)
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Figure 9. Participants with Pulmonary Tuberculosis (Sputum Diagnosis 3 as confirmed by Culture at 8
weeks)
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Table 1. Reported Prevalence of TB and Reported Cases of MDR-TB by Countrya
Population

Year

Reported
Prevalence of TB10

Ecuador

2012

98/100,000

Reported Cases of
MDR-TB among
pulmonary TB
(New/Retreatment)
210/170

Peru

2012

121/100,000

890/1300

Brazil

2012

59/100,000

850/860

Mexico

2012

33/100,000

380/100

USA

2012

4.7/100,000

81/-

Type of Data
Source
World Health
Organization
Region: AMR
World Health
Organization
Region: AMR
World Health
Organization
Region: AMR
World Health
Organization
Region: AMR
World Health
Organization
Region: AMR

Reference

WHO Global Health
Repository Data10;
WHO ‘Ecuador’
Country TB Profile11
WHO Global Health
Repository Data10;
WHO ‘Peru’ Country
TB Profile12
WHO Global Health
Repository Data10;
WHO ‘Brazil’
Country TB Profile13
WHO Global Health
Repository Data10;
WHO ‘Mexico’
Country TB Profile14
WHO Global Health
Repository Data10;
WHO ‘USA’
Country TB Profile15

a

Source from WHO Global Health Repository and WHO Country TB Profile10, 11, 12, 13, 14, 15

Table 2. LTBI vs. TB Diseasea

Person with LTBI (Infected)

Person with TB Disease (Infectious)

Has a small amount of TB bacteria in his/her body
that are alive, but inactive

Has a large amount of active TB bacteria in his/her
body

Cannot spread TB bacteria to others
Does not feel sick, but may become sick if the
bacteria become active in his/her body
Usually has a TB skin test or TB blood test reaction
indicating TB infection
Radiograph is typically normal
Sputum smears and cultures are negative
Should consider treatment for LTBI to prevent TB
disease
Does not require respiratory isolation
Not a TB case

May spread TB bacteria to others
May feel sick and may have symptoms such as a
cough, fever, and weight loss
Usually has a TB skin test or TB blood test reaction
indicating infection
Radiograph may be abnormal
Sputum smears and cultures may be positive
Needs treatment for TB disease
May require respiratory isolation
A TB case

Adapted from Center for Disease and Control4
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Table 3. Laboratories Diagnosing TB by Culture and SSM by Countrya
Population

Year

Ecuador

2011

Laboratories
using Culture
per 5 million
5.8

Laboratories
using SSM per
5 million
2.2

Laboratories
using DST
per 5 million
0.3

Type of
Data
Source
Region:
AMR

Peru

2011

11.2

5.2

0.3

Region:
AMR

Brazil

2011

7.8

2

1.1

Region:
AMR

Mexico

2011

2.8

0.6

0.7

Region:
AMR

USA

2006

27.7

0.6

27.5

Region:
AMR

a

Source from WHO Global Health Observatory Data Repository57

Reference
WHO Global
Health
Repository
Data50
WHO Global
Health
Repository
Data50
WHO Global
Health
Repository
Data50
WHO Global
Health
Repository
Data50
WHO Global
Health
Repository
Data50

Table 4. Socio-Demographic and other characteristics of study subjects (n= 212), 1999-2000a
Subject Characteristics

No.

%

Mestizo (mixed Spanish-Quechua)

197

92.9

Afro-Ecuadorian

11

5.2

Ethnicity (self reported)

Indigenous

4

1.9

133

62.7

18-30 years

73

34.4

>30 years

139

65.6

110
102

51.9
48.1

Sex (% female)
Age

Formal Education
< 9 years
> 9 years

Adapted from Armijos et al.62
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Table 5. Smear Classification Reporting a

Adapted from CDC- Chapter 4:Diagnosis of TB Disease47

Table 6. Smear Classificationa

Smear Positive
At least 2 smears examined and
both positive 1- per 100 fields
(scanty) or greater

Indeterminate
Several possibilities, e.g.
• Only one smear
examined (whatever the
grading)
• 3 smears examined but
only one reported
positive
In either of these situations,
either further sputum smears or a
CXR are required before a
patient can be classified.

Adapted from WHO- TB/HIV Clinical Manual63
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Smear negative
At least two smears reported 0
negative

Table 7. Gender for Sample Size

Table 8. Comparison of sputum smear with 4th and 8th week Lowenstein-Jensen
culture
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Table 9. Added Value of Sputum Sample and Culture

Table 10. Single Drug-Resistance (n=18)
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Table 11. Multi-Drug-Resistance (n=50)

Table 12. Total of Drug-Resistance
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Table 13. Susceptibility Patterns
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